Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
22 08 2019
Historique:
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 23 6 2020
Statut: epublish

Résumé

The human antibody repertoire represents a largely untapped source of potential therapeutic antibodies and useful biomarkers. While current computational methods, such as next generation sequencing (NGS), yield enormous sets of data on the antibody repertoire at the sequence level, functional data is required to identify which sequences are relevant for a particular antigen or set of antigens. Here, we describe a method to identify and recover individual antigen-specific antibodies from peripheral blood mononuclear cells (PBMCs) from a human blood donor. This method utilizes an initial enrichment of mature B cells and requires a combination of phenotypic cell markers and fluorescently-labeled protein to isolate IgG memory B cells via flow cytometry. The heavy and light chain variable regions are then cloned and re-screened. Although limited to the memory B cell compartment, this method takes advantage of flow cytometry to interrogate millions of B cells and returns paired heavy and light chain sequences from a single cell in a format ready for expression and confirmation of specificity. Antibodies recovered with this method can be considered for therapeutic potential, but can also link specificity and function with bioinformatic approaches to assess the B cell repertoire within individuals.

Identifiants

pubmed: 31498318
doi: 10.3791/59809
doi:

Substances chimiques

Antibodies 0
Antigens 0
Biomarkers 0
Luminescent Proteins 0

Types de publication

Journal Article Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Stuart T Perry (ST)

World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson and Johnson.

Elissa Keogh (E)

World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson and Johnson.

Mike Morton (M)

World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson and Johnson.

Wouter Koudstaal (W)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson.

Gabriel Pascual (G)

World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson and Johnson; gpascual@its.jnj.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH